- Home
- PAC vs EXAS Comparison
PAC vs EXAS Comparison
Compare PAC & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAC
- EXAS
- Stock Information
- Founded
- PAC 1998
- EXAS 1995
- Country
- PAC Mexico
- EXAS United States
- Employees
- PAC N/A
- EXAS N/A
- Industry
- PAC Aerospace
- EXAS Medical Specialities
- Sector
- PAC Consumer Discretionary
- EXAS Health Care
- Exchange
- PAC Nasdaq
- EXAS Nasdaq
- Market Cap
- PAC 11.6B
- EXAS 9.9B
- IPO Year
- PAC 2006
- EXAS N/A
- Fundamental
- Price
- PAC $228.77
- EXAS $52.99
- Analyst Decision
- PAC Buy
- EXAS Strong Buy
- Analyst Count
- PAC 6
- EXAS 20
- Target Price
- PAC $207.50
- EXAS $70.26
- AVG Volume (30 Days)
- PAC 114.1K
- EXAS 2.9M
- Earning Date
- PAC 07-22-2025
- EXAS 08-06-2025
- Dividend Yield
- PAC 3.17%
- EXAS N/A
- EPS Growth
- PAC N/A
- EXAS N/A
- EPS
- PAC 0.86
- EXAS N/A
- Revenue
- PAC $1,435,598,195.00
- EXAS $2,828,128,000.00
- Revenue This Year
- PAC $57.91
- EXAS $14.61
- Revenue Next Year
- PAC $8.28
- EXAS $12.65
- P/E Ratio
- PAC $26.41
- EXAS N/A
- Revenue Growth
- PAC 14.67
- EXAS 11.57
- 52 Week Low
- PAC $146.62
- EXAS $39.97
- 52 Week High
- PAC $241.62
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- PAC 51.17
- EXAS 48.51
- Support Level
- PAC $225.17
- EXAS $51.37
- Resistance Level
- PAC $233.01
- EXAS $55.90
- Average True Range (ATR)
- PAC 4.75
- EXAS 2.37
- MACD
- PAC -0.33
- EXAS -0.00
- Stochastic Oscillator
- PAC 53.55
- EXAS 39.67
About PAC Grupo Aeroportuario Del Pacifico S.A. B. de C.V. Grupo Aeroportuario Del Pacifico S.A. de C.V. (each representing 10 Series B shares)
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.